EligibleTrials

PyL in Patients With High Risk and Biochemically Recurrent Prostate Cancer

Recruiting · NCT04700332 · Interventional (participants receive a specific treatment) · Lead sponsor: Hoag Memorial Hospital Presbyterian

View the official record on ClinicalTrials.gov →
Prostate Cancer

Interventions studied

DCFPyL PET/CT

What this trial is about

The standard of care imaging of prostate cancer metastases recommended by the National Comprehensive Cancer Network (NCCN), CT of the chest/abdomen/pelvis and bone scan, may be suboptimal. PyL is a novel PET tracer designed to detect prostate specific membrane antigen (PSMA) expressed on prostate cancer cells. PyL PET/CT may provide improved evaluation of clinically significant metastases in patients with prostate cancer.

Who can take part

Age range
18 Years and older
Sex
Male
Healthy volunteers
No - a diagnosis or condition is required
Phase
Phase 2
Study type
Interventional (participants receive a specific treatment)

Inclusion criteria

Exclusion criteria

Where it is running

1 location listed across 1 US state.

Read the full protocol, contacts and eligibility on ClinicalTrials.gov →

Get notified when new trials open

One email when new recruiting trials are added. Unsubscribe anytime.